GDB-17

See the following -

The Collateral Benefits of India's Open Source Drug Discovery Programme

Priyanka Pulla | Forbes India | April 9, 2014

India's Open Source Drug Discovery programme is struggling for lack of expertise and a research ecosystem. However, the programme's real contribution may be the creation of just such an ecosystem Read More »